Evotec SE: Positive Phase IIb Data for Investigational P2X3 Antagonist in Patients with Refractory Chronic Cough

Rhea-AI Summary

Evotec announces positive Phase IIb results for eliapixant (BAY1817080), a P2X3 receptor antagonist, aimed at treating refractory chronic cough. The trial demonstrated a statistically significant improvement in cough frequency over placebo after 12 weeks. The safety and tolerability profile of the drug was favorable. Evotec stands to receive a financial milestone payment upon Bayer initiating a Phase III study, as per their 2012 agreement. Further details are expected from Bayer.

Positive

• Successful Phase IIb trial indicates effective treatment for refractory chronic cough.
• Statistically significant improvement in 24-hour cough counts compared to placebo after 12 weeks.
• Favorable safety and tolerability profile of eliapixant.
• Potential financial milestone payment upon initiation of Phase III study.

Negative

• None.

HAMBURG, GERMANY / ACCESSWIRE / August 3, 2021 / Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480) announces that the Company has been informed by Bayer about positive Phase IIb results from a clinical trial evaluating the efficacy and safety of the investigational P2X3 receptor antagonist eliapixant (BAY1817080) in patients with refractory chronic cough. The underlying molecule is a P2X3 receptor antagonist in Bayer's clinical development pipeline originating from a former Evotec/Bayer multi-target research alliance. The primary efficacy outcome was met showing a statistically significant improvement in 24-hour cough counts per hour (average hourly cough frequency based on 24-hour sound recordings) over placebo after 12 weeks of treatment. The data showed a favourable safety and tolerability profile.

Under the agreement from 2012, Evotec would be entitled to its next financial milestone payment upon start of a Phase III clinical study, to be decided by Bayer.

More details of the study will be presented by Bayer.

Contact:

Dr Werner Lanthaler
Chief Executive Officer
Evotec SE
Manfred Eigen Campus
Essener Bogen 7, 22419
Hamburg, Germany
Phone: +49.(0)40.560 81-242
werner.lanthaler@evotec.com

SOURCE: Evotec SE

View source version on accesswire.com:
https://www.accesswire.com/658139/Evotec-SE-Positive-Phase-IIb-Data-for-Investigational-P2X3-Antagonist-in-Patients-with-Refractory-Chronic-Cough

FAQ

What are the results of Evotec's Phase IIb trial for eliapixant?

The Phase IIb trial for eliapixant showed a statistically significant improvement in cough frequency over placebo after 12 weeks.

What is the next step for Evotec following the Phase IIb results?

Evotec is set to receive a financial milestone payment when Bayer starts a Phase III clinical study for eliapixant.

What is eliapixant used for in clinical trials?

Eliapixant is a P2X3 receptor antagonist being evaluated for its efficacy and safety in patients with refractory chronic cough.

Who conducted the clinical trial for eliapixant?

The clinical trial for eliapixant was conducted by Bayer, with results reported to Evotec.

When were the positive results for eliapixant announced?

The positive results for eliapixant were announced on August 3, 2021.